Market Intelligence, Clinical Progress, and High-Purity Reagents for Anticoagulant & Hemophilia Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for Factor X (F10) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Zymogen & Activated) | Factor X (F10) Full-Length Recombinant Protein (Zymogen) & Factor Xa Recombinant Protein (Activated). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Gla domain, glycosylation). | View Factor X Products / View Factor Xa Products |
| Gene Delivery | Factor X (F10) Promise-ORF / Lentivirus. Full-length ORF for stable hepatocyte transduction. | View Factor X Products |
| Benchmark Control | Andexanet Alfa Reference (Decoy Factor Xa). Modified recombinant protein for antidote development reference. Also recombinant FXa inactive mutant (Andexanet alfa biosimilar), theoretical MW verified. | View Factor Xa Products |
| Validator | Factor X (F10) siRNA Set. Sequence Verified for knockdown verification in liver cell models. | View Factor X Products |
| Related Target: Factor II (Thrombin) | Critical off-target for selectivity screening; downstream coagulation node. | View Thrombin Products |
| Related Target: Factor VIIa | Upstream activator (TF-FVIIa complex); exogenous pathway key component. | View Factor VIIa Products |
| Related Target: Factor IX | Essential binding partner for FIXa-FX bispecific antibodies (Hemophilia A therapies). | View Factor IX Products |
| Related Target: Factor XI | Upstream coagulation target; critical for counter-screening and next-generation safer anticoagulants. | View Factor XI Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Zymogen vs. Active Protease Discrimination (FX vs FXa) | Distinct batches: Native Factor X (zymogen) vs. pre-activated Factor Xa, validated by chromogenic substrate S-2765 assay. |
| Species Cross-Reactivity (Human/Mouse/Cyno) | Human/Mouse/Cyno Factor X ortholog proteins available with >95% purity, Sequence Verified by Mass Spec. |
| Protease Selectivity Panel | Coagulation Factor Panel (Thrombin, VIIa, IXa, Plasmin) for off-target liability screening; comprehensive serine protease homolog panels verified by mass spec. |
| Functional Activity Standardization | Endotoxin Controlled (<1 EU/μg), preventing artifactual coagulation cascade activation in vitro. |
| Bispecific Bridging Controls | Biosimilar clinical benchmark proteins and antibodies available with controlled endotoxin levels for heterodimer bridging validation. |
| False Positives in Gene Regulation | Sequence-verified siRNA included for precise specificity checks. |
Live Factor X / F10 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for next-generation Factor X therapeutics is intensifying. Major players are shifting focus from traditional small-molecule Direct Oral Anticoagulants (DOACs) to sophisticated biologics including reversal agents (e.g., Andexanet alfa decoy proteins) and long-acting anticoagulants. As first-generation DOACs reach market saturation, the next wave of R&D targets antidote development and bridging bispecific antibodies designed to bypass classical coagulation cascade deficiencies. Strict control over structural conformation and activation states during preclinical screening is now pivotal for successful IND applications. Key players include Bayer, J&J, BMS, Pfizer (DOACs); Roche/Chugai, Novo Nordisk (bispecific antibodies for hemophilia A); AstraZeneca, Portola (reversal agents); and Alnylam/Sanofi (gene therapy/RNAi).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecules (DOACs) | Bayer, J&J, BMS, Pfizer | Thrombosis, Stroke Prevention | Selectivity Assay (Need High-Purity active FXa vs homologous proteases) |
| Bispecific Antibodies | Roche (Chugai), Novo Nordisk | Hemophilia A | Heterodimer Bridging Validation (Need precise FIXa and FX proteins) |
| Recombinant Proteins | AstraZeneca, Portola | DOAC Reversal | Affinity Binding (Need Mutant decoy proteins and wild-type standards) |
| Gene Therapy / RNAi | Alnylam, Sanofi | Rare Coagulation Disorders | Target Knockdown (Need sequence-verified specific siRNA sets) |
Structural & Functional Insights
Factor X (F10) is a vitamin K-dependent serine protease zymogen with key functional domains: Gla domain (calcium-dependent membrane binding), two EGF-like domains (first is calcium-binding), and a serine protease catalytic domain. Key mutations include dbSNP:rs5963 and rs5961 (UniProt VAR_014162, VAR_014163), and FA10D St. Louis II (VAR_065428) which causes strongly reduced activity and impaired activation by factor VIIa. These structural features underscore the importance of domain-specific reagents for studying activation, inhibition, and therapeutic intervention.